Evidence map›Paper›PMID 25201222›Full record

ArticleJournal of neurology2014

Costeff syndrome: clinical features and natural history.

Gilad Yahalom, Yair Anikster, Ruth Huna-Baron, Chen Hoffmann, Lubov Blumkin, Dorit Lev, Rakefet Tsabari, Zeev Nitsan, Sheera F Lerman, Bruria Ben-Zeev and 5 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of neurology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.

  1. Catching the Culprit: How Chorea May Signal an Inborn Error of Metabolism.Tremor and other hyperkinetic movements (New York, N.Y.) · 2023
    Pooled it
  2. Review
  3. Article
  4. Importance of lipids for upper motor neuron health and disease.Seminars in cell & developmental biology · 2021
    Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Eye involvement in inherited metabolic disorders.Therapeutic advances in ophthalmology
    Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 1 country.

Gilad YahalomParkinson Disease and Movement Disorders Clinic, Chaim Sheba Medical Center, Tel-Hashomer, Ramat Gan, 52621, Israel, gyahalom@gmail.com.
Yair Anikster
Ruth Huna-Baron
Chen Hoffmann
Lubov Blumkin
Dorit Lev
Rakefet Tsabari
Zeev Nitsan
Sheera F Lerman
Bruria Ben-Zeev
Ben Pode-Shakked
Shira Sofer
Avraham Schweiger
Tally Lerman-Sagie
Sharon Hassin-Baer
Sheba Medical Center · ILWolfson Medical Center · ILAcademic College of Tel Aviv-Yafo · ILEdmond and Lily Safra Children's Hospital · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Costeff syndrome (CS) is a rare autosomal-recessive neurological disorder, which is known almost exclusively in patients of Iraqi Jewish descent, manifesting in childhood with optic atrophy, ataxia, chorea and spastic paraparesis. Our aim was to study the clinical spectrum of CS and natural history using a cross-sectional study design. Consecutive patients with CS were recruited to the study. Patients were diagnosed based on clinical features, along with elevated urinary levels of methylglutaconic and methylglutaric acid, and by identification of the disease-causing mutation in the OPA3 gene in most. All patients were examined by a neurologist and signs and symptoms were rated. 28 patients with CS (16 males, 21 families, age at last observation 28.6 ± 16.1 years, range 0.5-68 years) were included. First signs of neurological deficit appeared in infancy or early childhood, with delayed motor milestones, choreiform movements, ataxia and visual disturbances. Ataxia and chorea were the dominant motor features in childhood, but varied in severity among patients and did not seem to worsen with age. Pyramidal dysfunction appeared later and progressed with age (r = 0.71, p < 0.001) leading to spastic paraparesis and marked gait impairment. The course of neurological deterioration was slow and the majority of patients could still walk beyond the fifth decade. While visual acuity seemed to deteriorate, it did not correlate with age. CS is a rare neurogenetic disorder that causes serious disability and worsens with age. Spasticity significantly increases over the years and is the most crucial determinant of neurological dysfunction.

Indexed as

AdolescentAdultAgedAgingChildChild, PreschoolChoreaCross-Sectional StudiesFemaleHumansInfantMaleMetabolism, Inborn ErrorsMiddle AgedMuscle SpasticityOptic AtrophyOPA3 protein, humanProteins

Identifiers

PMID25201222
OpenAlexW2095165327

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.